The expression of alternative checkpoints such as TIM-3 and LAG-3 also contributes to an immunosuppressive TME.225Recently, combination of nivolumab and relatlimab (anti-LAG-3) demonstrated favorable PFS compared to nivolumab monotherapy in patients with advanced treatment-naive melanoma in a phase III trial.288Compared to this, encouraging trial data on anti-TIM-3 are limited. The gene discussed is LAG3; the disease is melanoma.